All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PDL1 (CPS < 1) PDL1 (CPS >1) smoker (Current) smoker (Former) stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
Extensive stage SCLC (Es-SCLC) - 1st Line (L1), anti-PD-(L)1 vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CASPIAN (D ; all population), 2019 0.73 [0.59; 0.91]
IMpower-133, 2018 0.70 [0.54; 0.91]
KEYNOTE-604, 2020 0.80 [0.65; 0.99]
0.75 [0.66 ; 0.85 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 0% 1,393 low not evaluable deaths (OS) (extension)detailed results CASPIAN (D ; all population), 2019 0.75 [0.62; 0.91]
IMpower-133, 2018 0.76 [0.60; 0.96]
0.75 [0.65 ; 0.87 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018 2 0% 940 moderate not evaluable PFS (extension)detailed results CASPIAN (D ; all population), 2019 0.80 [0.66; 0.96]
IMpower-133, 2018 0.77 [0.63; 0.95]
0.79 [0.68 ; 0.90 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018 2 0% 940 moderate not evaluable progression or deaths (PFS)detailed results CASPIAN (D ; all population), 2019 0.78 [0.65; 0.94]
IMpower-133, 2018 0.77 [0.62; 0.96]
KEYNOTE-604, 2020 0.75 [0.61; 0.92]
0.77 [0.68 ; 0.86 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 0% 1,393 low not evaluable objective responses (ORR)detailed results CASPIAN (D ; all population), 2019 1.64 [1.11; 2.43]
IMpower-133, 2018 0.84 [0.56; 1.25]
KEYNOTE-604, 2020 1.49 [1.01; 2.21]
1.27 [0.85 ; 1.91 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 68% 1,393 low not evaluable objective responses (ORR) (extension)detailed results IMpower-133, 2018 0.84 [0.56; 1.25]
0.84 [0.56 ; 1.25 ] IMpower-133, 2018 1 0% 403 NA not evaluable AE (any grade)detailed results CASPIAN (D ; all population), 2019 1.61 [0.52; 4.99]
IMpower-133, 2018 14.63 [0.82; 259.59]
3.21 [0.43 ; 23.85 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018 2 49% 925 moderate not evaluable AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.96 [0.68; 1.37]
IMpower-133, 2018 1.16 [0.77; 1.76]
KEYNOTE-604, 2020 1.12 [0.73; 1.73]
1.06 [0.85 ; 1.33 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 0% 1,378 low not evaluable AE leading to death (grade 5)detailed results CASPIAN (D ; all population), 2019 0.86 [0.40; 1.85]
IMpower-133, 2018 0.35 [0.11; 1.11]
KEYNOTE-604, 2020 1.27 [0.56; 2.87]
0.81 [0.42 ; 1.55 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 38% 1,378 low not evaluable AE leading to treatment discontinuation (any grade)detailed results CASPIAN (D ; all population), 2019 1.00 [0.56; 1.80]
IMpower-133, 2018 3.96 [1.57; 9.99]
KEYNOTE-604, 2020 2.64 [1.38; 5.07]
2.08 [0.92 ; 4.69 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 75% 1,378 low not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.35; 2.90]
1.00 [0.35 ; 2.90 ] CASPIAN (D ; all population), 2019 1 0% 531 NA not evaluable SAE (any grade)detailed results CASPIAN (D ; all population), 2019 0.79 [0.55; 1.14]
IMpower-133, 2018 1.12 [0.74; 1.70]
0.93 [0.66 ; 1.31 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018 2 35% 925 moderate not evaluable SAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.77 [0.51; 1.15]
0.77 [0.51 ; 1.15 ] CASPIAN (D ; all population), 2019 1 0% 531 NA not evaluable STRAE (any grade)detailed results CASPIAN (D ; all population), 2019 0.66 [0.41; 1.05]
IMpower-133, 2018 1.26 [0.78; 2.06]
0.91 [0.48 ; 1.72 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018 2 72% 925 moderate not evaluable STRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.51 [0.30; 0.86]
0.51 [0.30 ; 0.86 ] CASPIAN (D ; all population), 2019 1 0% 531 NA not evaluable TRAE (any grade)detailed results CASPIAN (D ; all population), 2019 0.92 [0.52; 1.61]
IMpower-133, 2018 1.56 [0.68; 3.56]
KEYNOTE-604, 2020 2.05 [0.69; 6.09]
1.22 [0.77 ; 1.92 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 8% 1,371 moderate not evaluable TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.78 [0.55; 1.10]
IMpower-133, 2018 1.02 [0.68; 1.52]
KEYNOTE-604, 2020 1.12 [0.76; 1.65]
0.95 [0.76 ; 1.18 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 6% 1,371 low not evaluable TRAE leading to death (grade 5)detailed results CASPIAN (D ; all population), 2019 2.54 [0.49; 13.20]
IMpower-133, 2018 0.99 [0.20; 4.96]
KEYNOTE-604, 2020 1.00 [0.32; 3.15]
1.25 [0.55 ; 2.82 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 0% 1,371 low not evaluable TRAE leading to discontinuation (any grade)detailed results CASPIAN (D ; all population), 2019 1.17 [0.54; 2.50]
1.17 [0.54 ; 2.50 ] CASPIAN (D ; all population), 2019 1 0% 531 NA not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.75 [0.17; 3.38]
0.75 [0.17 ; 3.38 ] CASPIAN (D ; all population), 2019 1 0% 531 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results IMpower-133, 2018 3.99 [0.18; 89.04]
3.99 [0.18 ; 89.04 ] IMpower-133, 2018 1 0% 394 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.02; 50.78]
IMpower-133, 2018 0.99 [0.02; 50.14]
KEYNOTE-604, 2020 4.03 [0.18; 89.81]
1.85 [0.23 ; 14.67 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 0% 1,371 low not evaluable Alopecia TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.51 [0.25; 9.12]
IMpower-133, 2018 0.99 [0.02; 50.14]
KEYNOTE-604, 2020 0.50 [0.02; 14.95]
1.16 [0.27 ; 5.04 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 0% 1,371 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.52 [0.29; 0.91]
IMpower-133, 2018 1.18 [0.66; 2.12]
KEYNOTE-604, 2020 1.08 [0.63; 1.86]
0.87 [0.52 ; 1.45 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 60% 1,371 low not evaluable Arthritis TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.02; 50.78]
1.00 [0.02 ; 50.78 ] CASPIAN (D ; all population), 2019 1 0% 531 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.14; 7.18]
KEYNOTE-604, 2020 0.49 [0.12; 2.00]
0.63 [0.20 ; 1.96 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 0% 977 low not evaluable Colitis TRAE (grade 3-4)detailed results IMpower-133, 2018 3.99 [0.18; 89.04]
KEYNOTE-604, 2020 0.50 [0.04; 5.53]
1.11 [0.15 ; 8.06 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 7% 840 low not evaluable Constipation TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.02; 50.78]
IMpower-133, 2018 1.98 [0.07; 59.51]
KEYNOTE-604, 2020 0.25 [0.01; 5.54]
0.72 [0.10 ; 5.19 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 0% 1,371 low not evaluable Decreased appetite TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.06; 16.13]
IMpower-133, 2018 3.99 [0.18; 89.04]
KEYNOTE-604, 2020 0.12 [0.01; 2.34]
0.76 [0.11 ; 5.28 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 23% 1,371 low not evaluable Diabetes TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 8.14 [0.43; 154.70]
IMpower-133, 2018 0.99 [0.02; 50.14]
KEYNOTE-604, 2020 2.00 [0.07; 60.06]
3.09 [0.45 ; 21.45 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 0% 1,371 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.14; 7.18]
IMpower-133, 2018 4.02 [0.45; 36.30]
KEYNOTE-604, 2020 1.68 [0.40; 7.12]
1.77 [0.63 ; 4.94 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 0% 1,371 low not evaluable Fatigue TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.67 [0.11; 4.02]
IMpower-133, 2018 3.00 [0.31; 29.09]
KEYNOTE-604, 2020 4.05 [0.45; 36.57]
1.70 [0.52 ; 5.57 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 0% 1,371 low not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.76 [0.36; 1.59]
IMpower-133, 2018 0.48 [0.18; 1.30]
0.64 [0.35 ; 1.17 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018 2 0% 925 moderate not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results IMpower-133, 2018 1.98 [0.07; 59.51]
1.98 [0.07 ; 59.51 ] IMpower-133, 2018 1 0% 394 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results IMpower-133, 2018 6.02 [0.30; 120.88]
KEYNOTE-604, 2020 6.07 [0.30; 121.85]
6.04 [0.72 ; 50.41 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.02; 50.78]
IMpower-133, 2018 0.99 [0.02; 50.14]
KEYNOTE-604, 2020 2.00 [0.07; 60.06]
1.32 [0.15 ; 11.31 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 0% 1,371 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.02; 50.78]
IMpower-133, 2018 0.99 [0.02; 50.14]
KEYNOTE-604, 2020 1.00 [0.02; 50.62]
1.00 [0.10 ; 9.62 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 0% 1,371 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.02; 50.78]
IMpower-133, 2018 0.99 [0.02; 50.14]
KEYNOTE-604, 2020 1.00 [0.02; 50.62]
1.00 [0.10 ; 9.62 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 0% 1,371 low not evaluable Increased lipase level TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 8.25 [1.02; 66.42]
8.25 [1.02 ; 66.42 ] CASPIAN (D ; all population), 2019 1 0% 531 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMpower-133, 2018 4.02 [0.45; 36.30]
4.02 [0.45 ; 36.30 ] IMpower-133, 2018 1 0% 394 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.08 [0.51; 2.28]
IMpower-133, 2018 1.25 [0.48; 3.24]
KEYNOTE-604, 2020 1.27 [0.69; 2.33]
1.20 [0.79 ; 1.83 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 0% 1,371 low not evaluable Myocarditis TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.02; 50.78]
KEYNOTE-604, 2020 1.00 [0.02; 50.62]
1.00 [0.06 ; 16.06 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 0% 977 moderate not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-604, 2020 2.00 [0.07; 60.06]
2.00 [0.07 ; 60.06 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Nausea TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.10 [0.01; 1.82]
IMpower-133, 2018 0.99 [0.06; 15.94]
KEYNOTE-604, 2020 1.00 [0.14; 7.16]
0.58 [0.14 ; 2.37 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 0% 1,371 low not evaluable Nephritis TRAE (grade 3-4)detailed results IMpower-133, 2018 1.98 [0.07; 59.51]
KEYNOTE-604, 2020 2.00 [0.07; 60.06]
1.99 [0.18 ; 22.08 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Neutropenia TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.63 [0.43; 0.92]
IMpower-133, 2018 0.91 [0.57; 1.44]
KEYNOTE-604, 2020 1.04 [0.71; 1.51]
0.83 [0.61 ; 1.14 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 44% 1,371 low not evaluable Pancreatitis TRAE (grade 3-4)detailed results IMpower-133, 2018 0.49 [0.04; 5.47]
KEYNOTE-604, 2020 2.00 [0.07; 60.06]
0.79 [0.11 ; 5.62 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Pancytopenia TRAE (grade 3-4)detailed results IMpower-133, 2018 0.33 [0.03; 3.17]
0.33 [0.03 ; 3.17 ] IMpower-133, 2018 1 0% 394 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.02; 50.78]
1.00 [0.02 ; 50.78 ] CASPIAN (D ; all population), 2019 1 0% 531 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMpower-133, 2018 3.99 [0.18; 89.04]
3.99 [0.18 ; 89.04 ] IMpower-133, 2018 1 0% 394 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results IMpower-133, 2018 6.02 [0.30; 120.88]
6.02 [0.30 ; 120.88 ] IMpower-133, 2018 1 0% 394 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 2.02 [0.18; 22.36]
IMpower-133, 2018 0.49 [0.04; 5.47]
KEYNOTE-604, 2020 6.07 [0.30; 121.85]
1.55 [0.35 ; 6.80 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 0% 1,371 low not evaluable Pruritus TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.02; 50.78]
1.00 [0.02 ; 50.78 ] CASPIAN (D ; all population), 2019 1 0% 531 NA not evaluable Rash TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.02; 50.78]
IMpower-133, 2018 8.06 [0.42; 153.52]
3.80 [0.36 ; 40.13 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018 2 0% 925 low not evaluable Severe skin reaction TRAE (grade 3-4)detailed results IMpower-133, 2018 0.99 [0.02; 50.14]
KEYNOTE-604, 2020 8.13 [0.43; 154.66]
3.81 [0.36 ; 40.15 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.56 [0.28; 1.11]
IMpower-133, 2018 1.36 [0.67; 2.73]
KEYNOTE-604, 2020 1.18 [0.67; 2.09]
0.98 [0.58 ; 1.63 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 47% 1,371 low not evaluable Thyroiditis TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.02; 50.78]
1.00 [0.02 ; 50.78 ] CASPIAN (D ; all population), 2019 1 0% 531 NA not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE-604, 2020 2.00 [0.07; 60.06]
2.00 [0.07 ; 60.06 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.25 [0.01; 5.56]
IMpower-133, 2018 0.66 [0.11; 3.97]
KEYNOTE-604, 2020 0.66 [0.11; 4.01]
0.57 [0.18 ; 1.86 ] CASPIAN (D ; all population), 2019, IMpower-133, 2018, KEYNOTE-604, 2020 3 0% 1,371 low not evaluable Alopecia AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.51 [0.25; 9.12]
KEYNOTE-604, 2020 0.50 [0.02; 14.95]
1.19 [0.24 ; 5.81 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 0% 977 moderate not evaluable Anaemia AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.45 [0.27; 0.76]
KEYNOTE-604, 2020 1.03 [0.62; 1.73]
0.69 [0.30 ; 1.54 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 80% 977 low not evaluable Asthenia AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.69 [0.40; 7.13]
KEYNOTE-604, 2020 0.72 [0.28; 1.82]
0.92 [0.42 ; 2.01 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 0% 977 low not evaluable Back pain AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 2.02 [0.18; 22.36]
KEYNOTE-604, 2020 2.00 [0.07; 60.06]
2.01 [0.28 ; 14.34 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 0% 977 moderate not evaluable Constipation AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 4.04 [0.18; 89.97]
KEYNOTE-604, 2020 0.50 [0.04; 5.53]
1.12 [0.15 ; 8.23 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 8% 977 low not evaluable Cough AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 4.04 [0.18; 89.97]
KEYNOTE-604, 2020 0.50 [0.04; 5.53]
1.12 [0.15 ; 8.23 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 8% 977 low not evaluable Decreased appetite AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.14; 7.18]
KEYNOTE-604, 2020 0.25 [0.03; 2.22]
0.54 [0.12 ; 2.33 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 0% 977 moderate not evaluable Diarrhoea AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.20; 5.02]
KEYNOTE-604, 2020 1.00 [0.32; 3.15]
1.00 [0.39 ; 2.55 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 0% 977 low not evaluable Dizziness AE (grade 3-4)detailed results KEYNOTE-604, 2020 1.00 [0.02; 50.62]
1.00 [0.02 ; 50.62 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Dyspnoea AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.69 [0.40; 7.13]
KEYNOTE-604, 2020 0.75 [0.17; 3.37]
1.14 [0.40 ; 3.24 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 0% 977 moderate not evaluable Fatigue AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.34 [0.30; 6.06]
KEYNOTE-604, 2020 1.51 [0.42; 5.44]
1.44 [0.54 ; 3.82 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 0% 977 low not evaluable Febrile neutropenia AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.82 [0.39; 1.69]
0.82 [0.39 ; 1.69 ] CASPIAN (D ; all population), 2019 1 0% 531 NA not evaluable Headache AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 2.01 [0.07; 60.21]
KEYNOTE-604, 2020 0.50 [0.02; 14.95]
1.00 [0.09 ; 11.09 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 0% 977 moderate not evaluable Hypertension AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 8.25 [1.02; 66.42]
8.25 [1.02 ; 66.42 ] CASPIAN (D ; all population), 2019 1 0% 531 NA not evaluable Hyperthyroidism AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.02; 50.78]
1.00 [0.02 ; 50.78 ] CASPIAN (D ; all population), 2019 1 0% 531 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-604, 2020 1.00 [0.02; 50.62]
1.00 [0.02 ; 50.62 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Increased Lipase Level AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 2.30 [0.70; 7.57]
2.30 [0.70 ; 7.57 ] CASPIAN (D ; all population), 2019 1 0% 531 NA not evaluable Leucopenia AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.23 [0.60; 2.56]
KEYNOTE-604, 2020 1.27 [0.69; 2.33]
1.25 [0.79 ; 2.00 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 0% 977 low not evaluable Nausea AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.20 [0.02; 1.70]
KEYNOTE-604, 2020 0.66 [0.11; 4.01]
0.40 [0.10 ; 1.61 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 0% 977 low not evaluable Neutropenia AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.64 [0.44; 0.94]
KEYNOTE-604, 2020 1.12 [0.77; 1.63]
0.85 [0.49 ; 1.46 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 75% 977 low not evaluable Peripheral oedema AE (grade 3-4)detailed results KEYNOTE-604, 2020 1.00 [0.02; 50.62]
1.00 [0.02 ; 50.62 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Pneumonia AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.55 [0.18; 1.66]
KEYNOTE-604, 2020 1.54 [0.67; 3.50]
0.98 [0.36 ; 2.67 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 53% 977 low not evaluable Pruritus AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.02; 50.78]
KEYNOTE-604, 2020 1.00 [0.02; 50.62]
1.00 [0.06 ; 16.06 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 0% 977 moderate not evaluable Pyrexia AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.50 [0.02; 15.00]
KEYNOTE-604, 2020 1.00 [0.06; 16.09]
0.76 [0.09 ; 6.52 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 0% 977 low not evaluable Rash AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 1.00 [0.02; 50.78]
KEYNOTE-604, 2020 6.07 [0.30; 121.85]
3.12 [0.29 ; 33.87 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 0% 977 low not evaluable Thrombocytopenia AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.58 [0.30; 1.12]
KEYNOTE-604, 2020 1.28 [0.73; 2.25]
0.88 [0.40 ; 1.91 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 69% 977 low not evaluable Vomiting AE (grade 3-4)detailed results CASPIAN (D ; all population), 2019 0.17 [0.01; 3.32]
KEYNOTE-604, 2020 0.50 [0.09; 2.73]
0.38 [0.09 ; 1.67 ] CASPIAN (D ; all population), 2019, KEYNOTE-604, 2020 2 0% 977 low not evaluable 0.2 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 01:06 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 162
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563
